Actually, dewophile was refering to the drug being safe and effective in the anemia indication. This is far different than handicapping the aproval path via this trial.
. no SPA . 15 patients on the placebo arm . a (presumed) Eastern European trial
Certainly NONE of these are high concerns, but they certainly do add doubt past dewophiles expectationcies for the drug itself.
It is a very safe bet that in general (not directed at RPRX here) investor optimisim is far too high in this setting.
Market Data 
Markets 
AI
